Amlodipine / Hydrochlorothiazide / Olmesartan
This combination medication is used to treat high blood pressure (hypertension) in patients who need multiple agents to achieve adequate control. It combines three different antihypertensive agents: a calcium channel blocker (amlodipine), a diuretic (hydrochlorothiazide), and an angiotensin receptor blocker (olmesartan), working through complementary mechanisms to lower blood pressure more effectively than single-agent therapy.
A triple-combination antihypertensive medication for patients with high blood pressure requiring multiple blood pressure-lowering agents.
Key facts at a glance
- RxNorm
- 1008801
- Generic
- Amlodipine / Hydrochlorothiazide / Olmesartan
- Class
- multi-ingredient
- Brands
- Tribenzor
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Treatment of hypertension (high blood pressure) in adults who are not adequately controlled on dual therapy or may benefit from triple antihypertensive therapy. Typically prescribed when single or dual agent therapy has failed to achieve target blood pressure goals.
The three components work through distinct mechanisms: amlodipine relaxes blood vessels by blocking calcium channels, hydrochlorothiazide reduces fluid volume by increasing urinary excretion of salt and water, and olmesartan blocks angiotensin II receptors to prevent blood vessel constriction. Together, they provide additive blood pressure-lowering effects through complementary pathways.
Not recommended during pregnancy due to potential harm to the fetus. May cause dizziness or low blood pressure, especially when starting or dose adjusting. Patients should report signs of kidney problems, severe dehydration, or electrolyte abnormalities. Avoid potassium supplements unless directed, as HCTZ can affect electrolytes while olmesartan may increase potassium.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 27, 2026. · Read our editorial policy